Table 2-3 Extra-anatomic bypass*⁹⁾.

Extra-anatomical bypass	Cases	Gender		Mortality	Backgrounds		Etiology			Graft materials*6)
		Male	Female	30-day mortality	Dialysis cases	Redo ope.	ASO	TAO	Others	Polyester	ePTFE	Autogenous vein	Others
Carotid–subclavian bypass	10	6	4	0	1	2	8	0	2	5	3	2	0
Axillo–axillary bypass	51	38	13	0	5	2	39	0	12	17	32	1	1
Axillo–femoral bypass*10)	397	280	117	10	55	55	377	0	20	151	239	15	5
Femoro–femoral cross-over bypass	961	819	142	6	79	114	934	0	26	269	577	56	6
Others	139	103	36	2	18	25	129	2	8	43	46	20	0
Total	1,532	1,223	309	17	155	193	1,462	2	67	479	877	91	12

*1) Bypass surgery combined with endovascular treatment is counted in both bypass category (Table 2-2) and endovascular category (Table 2-5). *2) Including redo operation only. Revision surgery cases should be counted in vascular complication part (see Table 8). *3) Including collagen disease related vasculitis, Behçet disease, fibromuscular dysplasia. *4) Postoperative irreversible brain complication. *5) Including percutaneous transluminal angioplasty (PTA), stent, and other endovascular means such as catheter atherectomy. *6) Only for open surgery. *7) Including aorto–iliac bypass or ilio–femoral bypasses. *8) Including popliteal–crural (or pedal) bypass. *9) Cases underwent extraanatomic bypass because of graft infection should not be included this category. Those cases are listed in vascular complication (Table 5). *10) A case underwent axillo–femoro–femoral crossover bypass is counted as one case. A case combined with additional contralateral side of axillilo-femoral bypass as second staged surgery is counted as 2 cases. Abbreviations; ASO: arteriosclerosis obriterance, TAO: thromboangiitis obliterans (Buerger’s disease), CAS: carotid artery stenting, CEA: carotid endarterectomy, PTA: percutaneous transluminal angioplasty, EVT: endovascular treatment.